title: Feasibility of sequential high-dose chemotherapy in advanced pediatric solid tumors.
abstract: The purpose of this study was to evaluate the feasibility and tumor response of 3 cycles of sequential high-dose chemotherapy (HDCT) in advanced pediatric solid tumor patients. Medical records of 11 children who underwent 2 consequent courses of reduced conditioning HDCT followed by final HDCT with autologous HSC infusion were reviewed in a retrospective manner. Each median time to an absolute neutrophil count > 0.5 x 10(9)/L was 12, 13, and 12 days. Major toxic reactions were fever, infection, and vomiting. One patient experienced transplantation-related mortality. Nine patients showed complete and partial responses to the therapy at 6 months follow-up after final HDCT. Finally, 6 patients are alive without evidence of disease at median follow-up of 24 months. Even though it is a preliminary result, the authors think that this treatment could be a feasible treatment option for advanced pediatric solid tumor patients.
authors.affiliation: Department of Pediatric Hematology-Oncology, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Seung Yeon
authors.initials: SY
authors.lastname: Kwon
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Won
authors.forename: Jung Woo
authors.initials: JW
authors.lastname: Han
authors.forename: Yoon Jung
authors.initials: YJ
authors.lastname: Shin
authors.forename: Chuhl Joo
authors.initials: CJ
authors.lastname: Lyu
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009447:Neuroblastoma / Q000188:drug therapy / Q000601:surgery; D036102:Peripheral Blood Stem Cell Transplantation; D012074:Remission Induction; D012189:Retrospective Studies; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000601:surgery; D016879:Salvage Therapy; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous